Drug Search Results
More Filters [+]

IPI-493

Alternative Names: ipi-493, ipi493, ipi 493
Latest Update: 2024-04-20
Latest Update Note: PubMed Publication

Product Description

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00724425)

Mechanisms of Action: HSP90 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IPI-493

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IPI-493-01

P1

Terminated

Oncology Unspecified

2011-07-01

IPI-493-02

P1

Terminated

Acute Myeloid Leukemia|Chronic Myeloid Leukemia

2011-07-01

Recent News Events